In the KEYNOTE-811 trial, the ORR of patients with metastatic HER2 positive GC was improved 12.8% when pembrolizumab was combined with trastuzumab and chemotherapy compared to just trastuzumab and chemotherapy. Here, ERBB2 is linked to gastric cancer.